By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AdkhabarAdkhabarAdkhabar
Notification Show More
Font ResizerAa
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Reading: DXS INTERNATIONAL PLC (AQSE: DXSP): Notice of 2025 Annual General Meeting
Share
Font ResizerAa
AdkhabarAdkhabar
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Search
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Follow US
Adkhabar > Blog > Health > DXS INTERNATIONAL PLC (AQSE: DXSP): Notice of 2025 Annual General Meeting
DXS INTERNATIONAL PLC (AQSE: DXSP): Notice of 2025 Annual General Meeting
Health

DXS INTERNATIONAL PLC (AQSE: DXSP): Notice of 2025 Annual General Meeting

GlobeNews Wire
Last updated: 24/11/2025 12:37 PM
GlobeNews Wire
Published: 24/11/2025
Share
SHARE

November 24, 2025 02:00 ET  | Source: DXS International PLC

Monday 24 November

DXS INTERNATIONAL PLC (AQSE: DXSP)

Notice of 2025 Annual General Meeting

The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, is pleased to announce that its Annual General Meeting is scheduled to take place on Thursday 18th December at 11.30 at Elm House, Tanshire Park, Shackleford Road. Elstead, Surrey GU8 6LB.

For further information in relation to the AGM, shareholders should refer to the Notice of Annual General Meeting and the AGM Letter which have been despatched to shareholders. Copies of these documents, along with the Company’s Annual Report for the year ended 30 April 2025, are available for download from the Company’s website https://www.dxs-systems.co.uk/corporate-documents.php

The Directors of DXS International plc accept responsibility for this announcement. This announcement contains information which, prior to its disclosure, was inside information as stipulated under Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310 (as amended).

Contacts:

David Immelman

DXS International plc

www.dxs-systems.com

01252 719800
AQSE Corporate Broker and Corporate Advisor

Hybridan LLP

Claire Louise Noyce

 

020 3764 2341

Notes to Editors

About DXS:

DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively and which should significantly contribute towards the NHS achieving its projected efficiency savings.

Zoomlion Recognized as Top-Tier Smart Factory at 2025 World Intelligent Manufacturing Conference
Millionaires on the Move: UK Braces for Historic Wealth Flight as Global Migration Peaks
SEMI Reports Global Semiconductor Equipment Billings Increased 21% Year-Over-Year in Q1 2025
Godrej Industries Group’s Assistive Tech Conference promotes accessible and equitable workplaces in India
Abu Dhabi Royal Equestrian Arts, the World’s Fifth School of Classical Horsemanship, Officially Opens Its Doors
TAGGED:2025annualaqseAquis Stock Exchange:DXSP.AQdxsdxspGB00B2Q6HZ92generalICAP EUROPE:DXSPinternationalmeetingnewsnoticeplc
Share This Article
Facebook Email Print
- Advertisement -

Follow US

Find US on Social Medias
FacebookLike
XFollow
YoutubeSubscribe

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!
Popular News
Brain Navi Biotechnology’s NaoTrac performs first surgeries in Spain
News

Brain Navi Biotechnology’s NaoTrac performs first surgeries in Spain

12/08/2025
Datavault AI, Music Dash and NFHITS Partner to Transform Music Data Tracking Display and Monetization Through Patented Inaudible Tones, AI and Blockchain Technology
Reebok Announces LongTerm Partnership with Major Champion Bryson DeChambeau and Crushers GC
Final Call for Entries: Submission Deadline Nears for the Seoul Design Award 2025
Inmagene Doses First Patient in the ADAPTIVE Phase 2b Trial of IMG-007, a Nondepleting Anti-OX40 mAb with an Extended Half-life, in Patients with Moderate-to-Severe Atopic Dermatitis
- Advertisement -
- Advertisement -
- Advertisement -

Categories

  • Automobile
  • Entertainment
  • E-Sports
  • Food
  • Health
  • Technology
  • LifeStyle
  • Travel

About Us

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.
Quick Link
Top Categories
  • Entertainment

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

AdkhabarAdkhabar
Copyright © 2021 - 2025 AdKhabar. All Rights Reserved. POWERED BY Life Care News.
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?